Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 6
Submit an article Journal homepage
10,485
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

Nizar J. Bahlisa Tom Baker Cancer Centre, Calgary, AB, CanadaCorrespondence[email protected]
View further author information
,
David S. Siegelb John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USAORCID Iconhttps://orcid.org/0000-0002-3604-2574View further author information
ORCID Icon,
Gary J. Schillerc David Geffen School of Medicine, University of California, Los Angeles, CA, USAView further author information
,
Christy Samarasd Cleveland Clinic, Cleveland, OH, USAView further author information
,
Michael Sebage McGill University Health Centre, Montreal, QC, CanadaView further author information
,
Jesus Berdejaf Sarah Cannon Research Institute, Nashville, TN, USAView further author information
,
Siddhartha Gangulyg Houston Methodist Hospital, Houston, TX, USAView further author information
,
Jeffrey Matoush Colorado Blood Cancer Institute, Denver, CO, USAView further author information
,
Kevin Songi Vancouver General Hospital, Vancouver, BC, CanadaView further author information
,
Christopher S. Seetc David Geffen School of Medicine, University of California, Los Angeles, CA, USAView further author information
,
Mirelis Acosta-Riveraj Fundación de Investigación, San Juan, Puerto RicoView further author information
,
Michael Bark Stamford Hospital, Stamford, CT, USAView further author information
,
Donald Quickl Joe Arrington Cancer Research and Treatment Center, Lubbock, TX, USAView further author information
,
Bertrand Anzm Tennessee Oncology, Chattanooga, TN, USAView further author information
,
Gustavo Fonsecan Florida Cancer Specialists, St Petersburg, FL, USAView further author information
,
Weiyuan Chungo Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Kim Leeo Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Jorge Mourop Celgene International Sàrl, A Bristol-Myers Squibb Company, Boudry, SwitzerlandView further author information
,
Amit Agarwalo Bristol Myers Squibb, Princeton, NJ, USAView further author information
&
Donna Reeceq Princess Margaret Cancer Centre, Toronto, ON, CanadaView further author information
 show all
Pages 1407-1417 | Received 21 Sep 2021, Accepted 09 Jan 2022, Published online: 08 Feb 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.